IntelGenx To Present at Biotech Showcase(TM) 2018
January 04 2018 - 08:00AM
IntelGenx Corp. (TSX VENTURE:IGX) (OTCQX:IGXT) (the "Company"
or "IntelGenx") today announced that its President and Chief
Executive Officer, Dr. Horst Zerbe, is scheduled to present an
overview of the Company’s business at the 10th Annual Biotech
Showcase™ conference on Tuesday, January 9 at 9:00 a.m.
Pacific Time at the Hilton San Francisco Union Square Hotel.
The presentation will be webcast live and
archived for 90 days on the Company's website, at
www.intelgenx.com, under "Investors".
Andre Godin, Executive Vice President and Chief
Financial Officer, and Dr. Dana Matzen, Vice President Business and
Corporate Development, from IntelGenx will also be available for
one-on-one meetings in San Francisco from January 8 through 10. To
arrange an investor meeting with IntelGenx, please contact Stephen
Kilmer (stephen@intelgenx.com) and to arrange a business
development meeting please contact Dr. Laëtitia Rodes
(laetitia@intelgenx.com).
About IntelGenx:
Established in 2003, IntelGenx is a
leading oral drug delivery company primarily focused on the
development and manufacturing of innovative pharmaceutical oral
films based on its proprietary VersaFilm™ technology platform.
IntelGenx' highly skilled team provides
comprehensive pharmaceuticals services to pharmaceutical partners,
including R&D, analytical method development, clinical
monitoring, IP and regulatory services. IntelGenx'
state-of-the-art manufacturing facility, established for the
VersaFilm™ technology platform, supports lab-scale to pilot and
commercial-scale production, offering full service capabilities to
its clients. More information about the company can be found
at www.intelgenx.com.
Forward-Looking Statements:
This document may contain forward-looking
information about IntelGenx' operating results and business
prospects that involve substantial risks and uncertainties.
Statements that are not purely historical are forward-looking
statements within the meaning of Section 21E of the Securities
Exchange Act of 1934, as amended, and Section 27A of the Securities
Act of 1933, as amended. These statements include, but are not
limited to, statements about IntelGenx' plans, objectives,
expectations, strategies, intentions or other characterizations of
future events or circumstances and are generally identified by the
words "may," "expects," "anticipates," "intends," "plans,"
"believes," "seeks," "estimates," "could," "would," and similar
expressions. All forward looking statements are expressly qualified
in their entirety by this cautionary statement. Because these
forward-looking statements are subject to a number of risks and
uncertainties, IntelGenx' actual results could differ
materially from those expressed or implied by these forward-looking
statements. Factors that could cause or contribute to such
differences include, but are not limited to, those discussed under
the heading "Risk Factors" in IntelGenx' annual report on Form
10-K, filed with the United States Securities and Exchange
Commission and available at www.sec.gov, and also filed with
Canadian securities regulatory authorities and www.sedar.com.
IntelGenx assumes no obligation to update any such
forward-looking statements.
Each of the TSX Venture Exchange and OTCQX has
neither approved nor disapproved the contents of this press
release.
Source: IntelGenx Technologies Corp.
Contacts :
Stephen Kilmer Investor Relations (514) 331-7440 ext 232
stephen@intelgenx.com
Andre Godin, CPA, CA Executive Vice-President and CFO (514)
331-7440 ext 203 andre@intelgenx.com
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Feb 2024 to Mar 2024
Intelgenx Technologies (TSXV:IGX)
Historical Stock Chart
From Mar 2023 to Mar 2024